Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 208-534-8 | CAS number: 532-32-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Direct observations: clinical cases, poisoning incidents and other
Administrative data
- Endpoint:
- direct observations: clinical cases, poisoning incidents and other
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Unclear if a double-blind clinical trial. No record of performance to GCP. No control group. Dose mixing for each subject. Very limited number of subjects in trial. Results should be treated as preliminary at best.
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 990
- Report date:
- 1990
Materials and methods
- Study type:
- study with volunteers
- Endpoint addressed:
- basic toxicokinetics
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Pharmacokinetic clinical trial using randomized oral dosing of a weekly dose of the test substance for three weeks to six volunteers with measurement of plasma concentrations of benzoic acid and hippuric acid and urinary concentrations of hippuric acid.
- GLP compliance:
- not specified
Test material
- Reference substance name:
- Sodium benzoate
- EC Number:
- 208-534-8
- EC Name:
- Sodium benzoate
- Cas Number:
- 532-32-1
- Molecular formula:
- C7H6O2.Na
- IUPAC Name:
- sodium benzoate
- Reference substance name:
- Benzoic acid, sodium salt
- IUPAC Name:
- Benzoic acid, sodium salt
- Details on test material:
- No data given
Constituent 1
Constituent 2
Method
- Type of population:
- general
- Subjects:
- - Number of subjects exposed: six
- Sex: male
- Age: 22 to 34 y (mean 28.8 y)
- Race:
- Demographic information:
- Known diseases: No
- Other: - Ethical approval:
- confirmed and informed consent free of coercion received
- Route of exposure:
- oral
- Reason of exposure:
- intentional
- Exposure assessment:
- measured
- Details on exposure:
- Three different doses (40, 80 and 160 mg/kg) of the substance dissolved in 300 mL water were orally administered to each volunteer in randomized sequence, at least one week apart. The volunteers ate a constant diet containing 1.5 g/kg/day protein for 3 days before each of the trial days. Subjects fasted for 6 h after dosing but with free access to tap water.
- Examinations:
- Benzoic acid and hippuric acid in plasma and urine were determined: Blood samples were collected at 0 (predose), 0.5, 1, 1.5, 2, 3, 4.5, 6, 9 and 12 h postdose. Urinary samples were collected at the following intervals: - 1.5 to 0 (baseline), 0 to 1.5, 1.5 to 3, 3 to 4.5, 4.5 to 6, 6 to 9, 9 to 12 and 12 to 24 h postdose.
- Medical treatment:
- None stated
Results and discussion
- Clinical signs:
- No information provided
- Results of examinations:
- Individual data on plasma benzoic acid and hippuric acid concentrations and % dose of hippuric acid excreted in urine with time in the six volunteers are shown in Fig. 1 (see attached document).
The post-absorption phase benzoic acid concentration-time curves revealed a so-called "hockey stick" appearance, and the slopes of the "shafts" increased with increasing doses of the test substance, as seen in Fig. 1 (left panel). The mean values for the declining slopes of the plasma benzoic acid concentration-time data were 35.3, 75.6 and 84.7 μg.mL/h after the test substance 40, 80 and 160 mg/kg. Plasma hippuric acid concentrations rose rapidly and the observed Cmax values were comparable after the three doses (Fig. 1, middle panel). The urinary excretion rates of hippuric acid ranged from 0.087 to 0.377 mg/kg/h when no test substance was administered. The cumulative urinary excretion of hippuric acid reached a plateau by 6 h after the 40 and 80 mg/kg doses in all individuals (right panel) and by 12 h after the 160 mg/kg dose in 4 of 6 individuals.
The relationships between the dose of the test substance and the AUC of benzoic acid and between the dose of test substance and the AUC of hippuric acid are illustrated in Fig. 2 (attached document). There was a disproportionate increase in the AUC of benzoic acid (left panel), but not of hippuric acid (right panel), with increasing doses of test substance. The corresponding mean AUC values of plasma benzoic acid after test substance 80 and 160 mg/kg were 3.7 and 12.0 times greater than after the 40 mg/kg dose. The mean AUCs of hippuric acid, however, were roughly proportional to the dose of test substance, the mean AUCs after the doses of 80 and 160 mg/kg test substance being 2.0 and 4.2 times greater than after 40 mg/kg.
The mean cumulative amounts of hippuric acid excreted in urine were 82.9 (4.7), 90.3 (5.4) and 73.1 (2.1) % of the administered doses of 40, 80 and 160 mg/kg test substance, respectively. - Effectivity of medical treatment:
- No information provided
- Outcome of incidence:
- No information provided
Any other information on results incl. tables
Model-independent pharmacokinetic parameters of benzoic acid and hippuric acid
Dose of the test substance (mg/kg) |
Benzoic acid |
Hippuric acid |
||||||
Cmax(μg/mL) |
tmax(h) |
AUC (μg·h/mL) |
Cmax(μg/mL) |
tmax(h) |
AUC (μg·h/mL) |
Ae (% of dose) |
CLR(L/h/kg) |
|
40 |
99.7 |
0.5 |
104.4 |
30.9 |
1.3 |
53.7 |
82.9 |
0.53 |
80 |
202.8 |
0.8 |
385.4 |
35.0 |
2.1 |
109.3 |
90.3 |
0.57 |
160 |
336.5 |
1.8 |
1257.0 |
36.9 |
4.1 |
223.5 |
73.1 |
0.45 |
Cmax=maximum plasma concentration;
tmax=time to reach maximum concentration;
AUC=the area under the plasma concentration-time curve;
Ae=amount of hippuric acid excreted in urine extrapolated to infinity.
Applicant's summary and conclusion
- Conclusions:
- The results showed that the AUC of benzoic acid, but not of hippuric acid, increases disproportionately with increasing oral doses of the test substance from 40 to 160 mg/kg: the respective AUCs of benzoic acid after the 80 and 160 mg/kg doses were 3.7 and 12.0 times greater than after the 40 mg/kg dose. This finding indicates that the biotransformation of benzoic acid to hippuric acid follows saturable or Michaelis-Menten kinetics in humans following oral the test substance. Indeed, the graph of the test substance dose versus the AUC of benzoic acid showed a curvilinear relationship, like that derived from Michaelis-Menten kinetic behaviour.
- Executive summary:
Plasma concentration-time data for benzoic and hippuric acids and urinary excretion-time data for hippuric acid were analyzed simultaneously after oral doses of 40, 80 or 160 mg/kg the substance administered at least one week apart to 6 healthy subjects. The mean AUCs of benzoic acid after the doses of 80 and 160 mg/kg of the substance were 3.7 and 12.0 times greater, respectively, than after 40 mg/kg. However, the mean AUC of hippuric acid was roughly proportional to the test substance doses. The observed data were explained by a onecompartment model with first-order rate absorption and Michaelis-Menten elimination of benzoic acid, together with a one-compartment model with first-order elimination for hippuric acid.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.